Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to 90 Years; no BMI minimum stated; conditions: Heart Failure Preserved Ejection Fraction; Epicardial Adipose Tissue
- Interventions
- GLP-1RA
- Conditions
- Heart Failure Preserved Ejection Fraction; Epicardial Adipose Tissue
- Phase and size
- Phase 4 · 192 participants
- Dates
- Start 2025-11-20
Primary completion 2029-09 - Sponsor
- University of Virginia (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Epicardial adipose tissue (EAT) fatty acid composition (FAC)Baseline, 3 months (self-control period), and 9-months (6 months post semaglutide treatment)
02Eligibility
Who can take part
Inclusion Criteria: * Age ≥ 18 years - 90 years; * LVEF ≥ 50%; * ≥ 2 risk factors for HFpEF or symptoms that could be related to HFpEF (e.g., dyspnea, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, pulmonary edema, etc); * Not currently being treated with GLP-1RA therapy. Exclusion Criteria: * • Previously or currently reduced EF (\<50%), including heart transplant; (2) Obstructive un-revascularized coronary disease by coronary CT or invasive coronary angiography; * MI/PCI/CABG within the past 6 months; * Untreated severe stenotic or regurgitant valvular disease; * Infiltrative cardiomyopathy (Fabry/HCM/sarcoid/amyloid, etc); * Myocarditis; * Claustrophobia/inability to tolerate MRI; * Implants that are a contraindication for MRI or may negatively impact image quality (e.g. pacemakers and ICDs); * Active systemic inflammatory disorder; * Atrial fibrillation with rapid ventricular response at time of study; and * Hemodynamic instability * Pregnancy * Prisoners * Inability to provide informed consent Exclusion Criteria for Optional Cardiac Stress Imaging Procedure * allergy to gadolinium-based contrast agents * Acute kidney injury * Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m² * Hepatorenal syndrome * History of liver transplant * High-grade atrioventricular (AV) block * Active asthma exacerbation * Known allergy to vasodilator agents * Recent seizure
03Change log
Registry changes
No changes recorded since the trial was added.